Tiglutik (riluzole) Oral Suspension 50 mg/10 mL (5 mg/mL), 600 mL (two bottles/300 mL each), RX o...

FDA Recall #D-0115-2024 — Class II — October 20, 2023

Recall #D-0115-2024 Date: October 20, 2023 Classification: Class II Status: Terminated

Product Description

Tiglutik (riluzole) Oral Suspension 50 mg/10 mL (5 mg/mL), 600 mL (two bottles/300 mL each), RX only, Manufactured for ITF Pharma, Inc., Berwyn, PA 19312 USA NDC:70726-0303-1 (carton) and 70726-0303-2 (bottle)

Reason for Recall

Failed Viscosity Specifications: Out-of-specification test results for viscosity

Recalling Firm

ITF PHARMA INC — Berwyn, PA

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

1,792 bottles

Distribution

Distributed to one distributor in TN who may have further distributed.

Code Information

LOT# 2231901, Exp. 11/30/2025; 2307901, Exp. 03/31/2026

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated